On June 3, Regeneron Pharmaceuticals rose 3.07% in regular trading, trading at $621.42/share, with trading volume of approximately $211 million. Multiple positive catalysts converged to drive the stock higher.

On the news front, the World Health Organization recommended Regeneron's monoclonal antibody Maftivimab for use in the current Bundibugyo-type Ebola virus outbreak under an investigational framework. Research data demonstrated that Maftivimab exhibits broad antiviral activity in vitro against multiple Ebola virus species, including the Bundibugyo virus, providing new scientific support for its potential therapeutic application scope. The drug has been recommended as a monotherapy for further study during the ongoing outbreak.

Additionally, Regeneron expanded its collaboration with CytomX Therapeutics, securing options on six additional targets. Under the new agreement, Regeneron paid an upfront fee, with combined potential milestone payments from existing and new programs reaching approximately $4 billion, significantly broadening the partnership's scope and reinforcing Regeneron's pipeline expansion strategy.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)